資訊> 企業(yè)新聞> 2020ESMO中國(guó)之光|恒瑞醫(yī)藥多項(xiàng)研究成果奏響國(guó)產(chǎn)原研藥最強(qiáng)音

2020ESMO中國(guó)之光|恒瑞醫(yī)藥多項(xiàng)研究成果奏響國(guó)產(chǎn)原研藥最強(qiáng)音

發(fā)布日期：2020-08-19 瀏覽次數(shù)：282

2020 年歐洲腫瘤內(nèi)科學(xué)會(huì)(ESMO)年會(huì)將于9 月14 日-10 月18 日在線上召開(kāi)，其中9 月19 日-21日的science weekend 將有眾多腫瘤領(lǐng)域新數(shù)據(jù)公布。作為歐洲最負(fù)盛名及最具影響力的腫瘤學(xué)會(huì)議，本次會(huì)議將展示腫瘤學(xué)的最新進(jìn)展，搭建學(xué)術(shù)研究與臨床實(shí)踐溝通的橋梁。

作為中國(guó)創(chuàng)新藥物研發(fā)的先行者與領(lǐng)跑者，恒瑞醫(yī)藥多款研發(fā)藥物再次登錄國(guó)際舞臺(tái)，治療領(lǐng)域涵蓋消化道腫瘤、肺癌、骨肉瘤、乳腺癌、頭頸部腫瘤、血液腫瘤、婦科腫瘤等多個(gè)領(lǐng)域。

今天，先讓我們一睹為快，有哪些研究即將亮相！

2020ESMO大會(huì) 網(wǎng)站內(nèi)容.png

★肺癌★

ACTIVE: Apatinib plus gefitinib versus?placebo plus gefitinib as first-line treatment for advanced non-squamous non-small-cell lung cancer patients with activating EGFR mutations: a multicentered, randomized,double-blind, placebo-controlled phase IIItrial (CTONG1706)

甲磺酸阿帕替尼一線聯(lián)合吉非替尼治療晚期EGFR 突變NSCLC 的III 期臨床研究

報(bào)告形式：LBA

講者：Zhangli

1267P - Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment?for advanced squamous NSCLC

卡瑞利珠單抗聯(lián)合阿帕替尼二線治療晚期鱗狀NSCLC??

報(bào)告形式：E-Poster

講者：Guanghui ?Gao(Shanghai, China)? ??

日期：2020/09/17

1366P - Efficacy ?and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer ?with EGFR-TKI resistance (date updated)? ?

阿帕替尼聯(lián)合EGFR-TKI治療EGFR-TKI耐藥后的晚期NSCLC(數(shù)據(jù)更新)

報(bào)告形式：E-Poster

講者：Ruifen ?Tian(Taiyuan, China)

日期：2020/09/17

1804P - The Efficacy of Apatinib plus Topotecan as Laterline Therapy for Advanced Small Cell Lung Cancer

阿帕替尼聯(lián)合拓?fù)涮婵底鳛橥砥谛〖?xì)胞肺癌后線治療療效?

報(bào)告形式：E-Poster

講者：Haifeng Qin(Beijing, China)? ??

日期：2020/09/17

1805P -?Apatinib ?combined with irinotecan in the treatment of small cell lung cancer: a phase ?2, single-arm, prospective study

阿帕替尼聯(lián)合伊立替康治療小細(xì)胞肺癌：II 期、單臂、前瞻性研究?

報(bào)告形式：E-Poster

講者：Yanbin ?Zhao(Harbin, China)

日期：2020/09/17

★肝細(xì)胞癌★

983P - Camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): an open-label, multi-center, phase 2 trial.

卡瑞利珠單抗聯(lián)合阿帕替尼治療晚期肝細(xì)胞癌(RESCUE)：開(kāi)放標(biāo)簽、多中心、II 期研究??

報(bào)告形式：E-Poster

講者：Jianming ?Xu(Beijing, China)

日期：2020/09/17

985P - A phase 2 study of camrelizumab for advanced hepatocellular carcinoma: two-year outcomes and continued treatment beyond RECIST-defined progression.

卡瑞利珠單抗治療晚期肝細(xì)胞癌的II 期研究：RECIST 定義進(jìn)展后持續(xù)治療2 年結(jié)果

報(bào)告形式：E-Poster

講者：Zhenggang Ren(Shanghai, China)

日期：2020/09/17

81TiP - The? changes? of? immune? function??and? prognosis in advanced perihilar??cholangiocarcinoma? patients? by immunotherapy??combined? with different topical therapies

免疫療法聯(lián)合其他類型治療晚期肝門型膽管細(xì)胞癌患者的免疫功能及預(yù)后改變

報(bào)告形式：E-Poster

講者：Chao Zhao(Taiyuan,China)

日期：2020/09/17

★胃癌★

1452P - Phase I study of apatinib plus POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-na?ve advanced gastric cancer (TNAGC), the result including the dose level (dl) at 850mg

阿帕替尼聯(lián)合POF( 紫杉醇+FOLFOX) 治療初治晚期胃癌患者(TNAGC) 的I 期研究，包含850mg 劑量的結(jié)果?

報(bào)告形式：E-Poster

講者：Rongbo Lin(Fuzhou, Fujian, China)??

日期：2020/09/17

1455P - A single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric cancer

阿帕替尼聯(lián)合化療二線治療晚期胃癌患者的單臂、開(kāi)放標(biāo)簽、前瞻性、多中心研究??

報(bào)告形式：E-Poster

講者：Jifeng Feng(Nanjing, China)

日期：2020/09/17

1428P - Apatinib combined with docetaxel?in second-line treatment of advanced gastric?cancer: a prospective clinical study(data updated)

阿帕替尼聯(lián)合多西他賽二線治療晚期胃癌：前瞻性臨床研究(數(shù)據(jù)更新)

報(bào)告形式：E-Poster

講者：Mudan Yang(Taiyuan, China)

日期：2020/09/17

1434P - A prospective, multicenter, nonrandomized,controlled trial of Apatinib?plus perioperative chemotherapy with FLOT?protocol and surgery for the treatment of stage?III gastric cancer

阿帕替尼聯(lián)合FLOT 方案圍手術(shù)期化療及手術(shù)治療III 期胃癌的前瞻性多中心非隨機(jī)對(duì)照研究??

報(bào)告形式：E-Poster

講者：Jun Zhang(Shenyang, China)

日期：2020/09/17

442P - Camrelizumab combined with Apatinib?in the treatment of patients with advanced?gastric cancer and colorectal cancer ：One-arm?exploratory clinical trial

卡瑞利珠單抗聯(lián)合阿帕替尼治療晚期胃癌和結(jié)直腸癌：?jiǎn)伪厶剿餍耘R床研究??

報(bào)告形式：E-Poster

講者：Li Xiao(Xiamen, China)

日期：2020/09/17

1427P - A phase II study of neoadjuvant concurrent?chemoradiotherapy with apatinib for HER-2?negative Siewert type II and III adenocarcinoma?of esophagogastric junction

新輔助同步放化療聯(lián)合阿帕替尼治療Siewert II型、Ⅲ型HER2 陰性胃食管交界處腺癌的II 期臨床研究? ??

報(bào)告形式：E-Poster

講者：Qun Zhao(Shijiazhuang, China)

日期：2020/09/17

★食管癌★

1431P - Study on the safety and efficacy?of apatinib combined with concurrent?chemoradiotherapy in the treatment of nonoperative?esophageal cancer

阿帕替尼聯(lián)合同步放化療治療不可切除食管癌患者的療效和安全性? ??

報(bào)告形式：E-Poster

講者：Jingping Yu(Changzhou, China)

日期：2020/09/17

1501TiP - The changes of tumor immune?microenvironment in esophageal squamous?cell carcinoma patients intervened by different?neoadjuvant therapies

應(yīng)用不同的新輔助方案治療食管鱗癌的腫瘤免疫微環(huán)境的改變

報(bào)告形式：E-Poster

講者：Wei Li Wang(Taiyuan, China)? ??

日期：2020/09/17

1034P - Camrelizumab in the Treatment?of Patients with local advanced/metastatic?esophageal squamous cell carcinoma (ESCC)：a multi-center, prospective, cohort study

卡瑞利珠單抗治療局部晚期/轉(zhuǎn)移性食管鱗癌(ESCC)：多中心、前瞻性隊(duì)列研究

報(bào)告形式：E-Poster

講者：Qun Y. Zhu(Su zhou, China)

日期：2020/09/17

1503TiP - A Prospective Study of Apatinib in Combination with Neoadjuvant Concurrent Chemoradiotherapy for locally Advanced Esophageal Squamous Cell Carcinoma

阿帕替尼聯(lián)合同步放化療新輔助治療局部晚期食管鱗癌的前瞻性研究??

報(bào)告形式：E-Poster

講者：Jun Wang(Shijiazhuang, China)

日期：2020/09/17

★乳腺癌★

224P -?Neoadjuvant ?pyrotinib plus trastuzumab, docetaxel, and carboplatin in patients with ?HER2-positive early breast cancer: a single-group, multicenter, phase 2 study?

吡咯替尼聯(lián)合曲妥珠單抗、多西他賽、卡鉑新輔助治療HER2陽(yáng)性乳腺癌患者：?jiǎn)伪邸⒍嘀行摹I 期研究? ? ?

報(bào)告形式：E-Poster

講者：Zhenzhen ?Liu(Zhengzhou, China)

日期：2020/09/17

225P - Phase 2 study of pyrotinib plus albumin-bound?paclitaxel and trastuzumab as neoadjuvant treatment in?HER2-positive early or locally advanced breast cancer

吡咯替尼聯(lián)合白蛋白紫杉醇和曲妥珠單抗新輔助治療HER2 陽(yáng)性早期或局部晚期乳腺癌的II 期研究

報(bào)告形式：E-Poster

講者：Ting Luo(Chengdu, Sichuan, China)

日期：2020/09/17

294P - Pyrotinib and capecitabine for HER2–Positive metastatic breast cancer patients?with previously untreated brain metastases: A?single-group multicenter phase II study

吡咯替尼聯(lián)合卡培他濱治療既往未經(jīng)治療腦轉(zhuǎn)移的HER2 陽(yáng)性轉(zhuǎn)移性乳腺癌患者：?jiǎn)伪邸⒍嘀行摹I 期研究?

報(bào)告形式：E-Poster

講者：Min Yan(Zhengzhou, China)?

日期：2020/09/17

270P - Apatinib added to taxanes and platinum?neoadjuvant chemotherapy for patients with?triple-negative and HER2-positive breast?cancer: a multicenter, randomized, phase II,open-label trial

阿帕替尼聯(lián)合紫杉類和鉑類用于三陰性和HER2 陽(yáng)性乳腺癌的新輔助治療：多中心、隨機(jī)、II 期、開(kāi)放標(biāo)簽研究? ? ??

報(bào)告形式：E-Poster

講者：Yunjiang ?J. Liu(Shijiazhuang, China)?

日期：2020/09/17

15P - Study on the mechanism of apatinib?reversing tamoxifen resistance in breast?cancer?

阿帕替尼逆轉(zhuǎn)乳腺癌中他莫昔芬耐藥性的機(jī)制研究?

報(bào)告形式：E-Poster

講者：Qingxia ?Li(Shijiazhuang, China)??

日期：2020/09/17

★甲狀腺癌★

A Randomized Multicentered Phase 3 Study to Evaluate Apatinib in Subjects with Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer

阿帕替尼治療局部晚期或轉(zhuǎn)移性放射性碘治療分化型甲狀腺癌：多中心隨機(jī)III期研究

報(bào)告形式：LBA

講者：Yansong Lin

★鼻咽癌★

912MO - A single-arm, open-label, multicenter phase 2 study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥ 2 lines of chemotherapy: CAPTAIN study

卡瑞利珠單抗治療接受過(guò)2 線及以上化療后進(jìn)展的復(fù)發(fā)/ 轉(zhuǎn)移性鼻咽癌(NPC)患者的單臂、開(kāi)放標(biāo)簽、多中心、Ⅱ期研究：CAPTAIN

報(bào)告形式：Mini Oral

講者：Li Zhang(Guangzhou, China)

日期：2020/09/18

941P - Efficacy and Safety of Apatinib Combined with Capecitabine in Patients with Advanced Nasopharyngeal Carcinoma

阿帕替尼聯(lián)合卡培他濱治療晚期鼻咽癌的療效和安全性

報(bào)告形式：E-Poster

講者：XiuYu Cai(Guangzhou, China)

日期：2020/09/17

★淋巴瘤★

893MO - An open-label, single-center,phase II, single-arm trial of camrelizumab?combined with apatinib in patients with?relapsed or refractory peripheral T-cell?lymphoma

卡瑞利珠單抗聯(lián)合阿帕替尼治療復(fù)發(fā)/ 難治性外周T細(xì)胞淋巴瘤的開(kāi)放標(biāo)簽、單中心、II 期、單臂研究?

報(bào)告形式：Mini Oral

講者：Yan Xie(Beijing, China)? ?

日期：2020/09/18

Efficacy and safety of HHPG-19K for prophylaxis of chemotherapy-induced neutropenia in patients with lymphoma

硫培非格司亭用于化療導(dǎo)致粒細(xì)胞減少的淋巴瘤患者的療效和安全性??

報(bào)告形式：E-Poster

講者：Liping Su(Shanxi, China)? ??

日期：2020/09/17

★婦瘤★

840P - Famitinib malate plus camrelizumab for?recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical?cancer: an open-label, multicenter phase II study

法米替尼聯(lián)合卡瑞利珠單抗治療鉑類耐藥的卵巢/ 輸卵管/ 原發(fā)性腹膜癌和晚期宮頸癌：開(kāi)放標(biāo)簽、多中心、II 期研究??

報(bào)告形式：E-Poster

講者：Lingfang Xia(Shanghai, China)

日期：2020/09/17

★軟骨肉瘤★

1646P - Apatinib for treatment of inoperable?metastatic or locally advanced chondrosarcoma:?What we can learn about the biological behavior?of chondrosarcoma from a multicenter study

阿帕替尼治療不可手術(shù)的轉(zhuǎn)移或局部晚期軟骨肉瘤 ??

報(bào)告形式：E-Poster

講者：Lu Xie(Beijing, China)? ?

日期：2020/09/17

★其他★

1511P - A real world study of pyrotinib in?patients with HER-2 positive/mutations tumors?excluding breast cancer

吡咯替尼治療HER2 陽(yáng)性/ 突變腫瘤(乳腺癌除外)的真實(shí)世界研究?

報(bào)告形式：E-Poster

講者：Jun Qian(Suzhou, China)

日期：2020/09/17

38P - Study on human plasma concentration and serosal permeation of oral apatinib mesylate

甲磺酸阿帕替尼血漿濃度和漿膜通透性研究

報(bào)告形式：E-Poster

講者：Jian Shi(Shijiazhuang, China)

日期：2020/09/17

注：以上預(yù)告內(nèi)容為ESMO官網(wǎng)截至2020/08/11的最新信息，如需詳細(xì)內(nèi)容請(qǐng)至ESMO官網(wǎng)查閱。

文章推薦

錨定創(chuàng)新，行穩(wěn)致遠(yuǎn) | 一圖回顧復(fù)星醫(yī)藥2023年中期業(yè)績(jī)
html{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;line-height:1.6}bod

2023-08-29
恒瑞醫(yī)藥再次獲評(píng)江蘇重點(diǎn)培育和發(fā)展的國(guó)際知名品牌！
近日，江蘇省商務(wù)廳發(fā)布“2023—2025年度江蘇省重點(diǎn)培育和發(fā)展的國(guó)際知名品牌”名單，恒瑞醫(yī)藥憑借扎實(shí)的研發(fā)創(chuàng)新實(shí)力、國(guó)際領(lǐng)先的質(zhì)控體系以及取得的一系列國(guó)際化

2023-08-31
國(guó)際化重要進(jìn)展！恒瑞醫(yī)藥卡瑞利珠單抗聯(lián)合用藥三期臨床在美獲批
恒瑞醫(yī)藥自主研發(fā)的PD-1明星產(chǎn)品注射用卡瑞利珠單抗邁出國(guó)際化重要進(jìn)展。近日，恒瑞醫(yī)藥收到美國(guó)食品藥品監(jiān)督管理局（以下簡(jiǎn)稱“美國(guó)FDA”）關(guān)于同意注射用卡瑞利珠

2021-08-09
排名躍升，恒瑞醫(yī)藥再登“醫(yī)藥工業(yè)百?gòu)?qiáng)榜”！蟬聯(lián)“研發(fā)最佳”榜單首位
8月1日，2021年（第38屆）全國(guó)醫(yī)藥工業(yè)信息年會(huì)在濟(jì)南舉行。會(huì)上發(fā)布了備受矚目的“2020年度中國(guó)醫(yī)藥工業(yè)百?gòu)?qiáng)榜”及系列分榜單，恒瑞醫(yī)藥獲得2020年度中國(guó)

2021-08-02

職位推薦

微信掃一掃

300多萬(wàn)優(yōu)質(zhì)簡(jiǎn)歷

17年行業(yè)積淀

2萬(wàn)多家合作名企業(yè)

微信掃一掃使用小程序

2020ESMO中國(guó)之光|恒瑞醫(yī)藥多項(xiàng)研究成果 奏響國(guó)產(chǎn)原研藥最強(qiáng)音

職位推薦

微信掃一掃

2020ESMO中國(guó)之光|恒瑞醫(yī)藥多項(xiàng)研究成果奏響國(guó)產(chǎn)原研藥最強(qiáng)音